Compound
D0750 | 5alpha-dihydrotestosterone
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 13.30±6.16 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 17.34 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Danger |
Aggregated GHS information provided by 58 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H351 (98.28%): Suspected of causing cancer [Warning Carcinogenicity] H360 (96.55%): May damage fertility or the unborn child [Danger Reproductive toxicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P281, P308+P313, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (+)-Androstan-17.beta.-ol-3-one | (+)-Androstan-17beta-ol-3-one | (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadecan-5-one |
| (1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one | (5-alpha,17-beta)-17-Hydroxyandrostan-3-one | (5.alpha.,17.beta.)-17-Hydroxy-androstan-3-one |
| (5S,8R,10S,13S,17S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one | (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one | (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one |
| (5alpha,17beta)-17-hydroxyandrostan-3-one | 08J2K08A3Y | 17-.beta.-Hydroxy-5-.alpha.-androstan-3-one |
| 17-Hydroxy-androstan-3-one | 17-Hydroxyandrostan-3-one | 17-Hydroxyandrostan-3-one, (5.alpha.,17.beta.)- # |
| 17-beta-Hydroxy-5-alpha-androstan-3-one | 17-beta-hydroxyandrostan-3-one | 17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,10,11,12,13,14,15,16, 17-hexadecahydrocyclopenta[a]phenanthren-3-one |
| 17.beta.-Hydroxy-3-androstanone | 17b-Hydroxy-3-androstanone | 17beta-Hydroxy-3-androstanone |
| 17beta-Hydroxy-5alpha-androstan-3-one | 17beta-Hydroxy-5alpha-androstane-3-one | 17beta-Hydroxy-androstan-3-one |
| 17beta-Hydroxyandrostan-3-one | 17beta-hydroxy-3-oxo-5alpha-androstanone | 1d2s |
| 1kdk | 1t5z | 1t63 |
| 1t7r | 2ama | 4,5-alpha-Dihydrotestosterone |
| 4,5.alpha.-Dihydrotestosterone | 4,5a-Dihydrotestosterone | 4,5alpha-Dihydrotestosterone |
| 4-Dihydrotestosterone | 5-.alpha.-Androstanolone | 5-a-Androstanolone |
| 5-alpha-Androstan-17-beta-ol-3-one | 5-alpha-Androstan-3-one, 17-beta-hydroxy- | 5-alpha-Androstanolone |
| 5-alpha-Dihydrotestosterone | 5.alpha.,17.beta.-Hydroxyandrostan-3-one | 5.alpha.-Androstan-17.beta.-ol-3-one |
| 5.alpha.-Androstan-3-one, 17.beta.-hydroxy- | 5.alpha.-Dihydrotestosterone | 5.alpha.-Dihydroxytestosterone |
| 521-18-6 | 521S186 | 5A-Androstan-3-on-17B-ol |
| 5B-Androstan-3-on-17B-ol | 5a-Androstan-17b-ol-3-one | 5a-Dihydrotestosterone |
| 5alpha dihydrotestosterone | 5alpha,17beta-Hydroxyandrostan-3-one | 5alpha,17eta-Hydroxyandrostan-3-one |
| 5alpha-Androstan-17beta-ol-3-one | 5alpha-Androstan-17beta-ol-3-one, >=97.5% | 5alpha-Androstan-17beta-ol-3-one, VETRANAL(TM), analytical standard |
| 5alpha-Androstan-17beta-ol-3-one, purum, >=99.0% (TLC) | 5alpha-Androstan-3-one, 17beta-hydroxy- | 5alpha-Androstan-3-one, 17beta-hydroxy- (8CI) |
| 5alpha-Androstanolone | 5alpha-DHT | 5alpha-Dihydrotestosterone |
| 5alpha-Dihydrotestosterone (DHT) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; | 5alpha-Dihydroxytestosterone | 5alpha-dihydrotesosterone |
| AB0108935 | AC-16144 | AK173346 |
| AKOS015894892 | API0004234 | Anaboleen |
| Anabolex | Andractim | Andractim (TN) |
| Andrin | Androlone | Androstan-17.beta.-ol-3-one |
| Androstan-17b-ol-3-one | Androstan-17beta-ol-3-one | Androstan-3-one, 17-hydroxy-, (5a,17b)- |
| Androstan-3-one, 17-hydroxy-, (5alpha,17beta)- | Androstan-3-one, 17-hydroxy-, (5alpha,17beta)- (9CI) | Androstanolona |
| Androstanolona [INN-Spanish] | Androstanolone | Androstanolone (5alpha-Dihydrotestosterone |
| Androstanolone (5alpha-Dihydrotestosterone | Androstanolone (INN) | Androstanolone [INN] |
| Androstanolonum | Androstanolonum [INN-Latin] | BDBM18161 |
| BDBM50366473 | BIDD:ER0136 | BIDD:PXR0075 |
| C-18235 | C03917 | CAS-521-18-6 |
| CC-34536 | CHEBI:16330 | CHEMBL27769 |
| CS-5096 | Cristerona MB | D07456 |
| DB02901 | DHT | DSSTox_CID_2364 |
| DSSTox_GSID_22364 | DSSTox_RID_76558 | DTXSID9022364 |
| Dihydrotestosteron | EBD2157869 | EC 208-307-3 |
| EINECS 208-307-3 | Epitope ID:135868 | GS-6587 |
| GTPL2856 | GTPL3455 | HMS2272H05 |
| HY-A0120 | LG 152 | LMST02020042 |
| LS-19384 | MCULE-5987413622 | MLS001304063 |
| NCGC00091013-01 | NCGC00091013-02 | NCGC00091013-03 |
| NCGC00257456-01 | NCGC00258540-01 | NSC 10972 |
| NSC-10972 | NSC10972 | NVKAWKQGWWIWPM-ABEVXSGRSA-N |
| Neodrol | Proteina | Protona |
| Q411054 | SC-16121 | SCHEMBL15163 |
| SMR000058342 | STANOLONE | Stanaprol |
| Stanolon | Stanolone [BAN] | Stanolone) |
| Stanolone) 1.0 mg/ml in Acetonitrile | Stanorone | Testosterone, dihydro- |
| Tox21_111056 | Tox21_200987 | Tox21_303655 |
| UNII-08J2K08A3Y | Z-2983 | ZINC3814360 |
| [3H]-dihydrotestosterone | [3H]DHT | [3H]dihydrotestosterone |
| dihydrotestosterone | dihydrotestosterone (dht) | s4757 |